Cyclic penta- and hexaleucine peptides without N -methylation are orally absorbed

ACS Medicinal Chemistry Letters

Volumn 5, Issue 10, 2014, Pages 1148-1151

  Hill, Timothy A ^a   Lohman, Rink Jan ^a   Hoang, Huy N ^a   Nielsen, Daniel S ^a   Scully, Conor C G ^a   Kok, W Mei ^a   Liu, Ligong ^a   Lucke, Andrew J ^a   Stoermer, Martin J ^a   Schroeder, Christina I ^a   Chaousis, Stephanie ^a   Colless, Barbara ^a   Bernhardt, Paul V ^a   Edmonds, David J ^b   Griffith, David A ^b   Rotter, Charles J ^b   Ruggeri, Roger B ^b   Price, David A ^b   Liras, Spiros ^b   Craik, David J ^a   Fairlie, David P ^a   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PFIZER INC   (United States)

Author keywords

absorption; Oral bioavailability; peptides; permeability; rule of five

Indexed keywords

CYCLIC HEXALEUCINE; CYCLIC PENTALEUCINE; CYCLO HEPTALEUCINE DEXTRO LEUCINE; CYCLOPEPTIDE; CYCLOSPORIN A; HEXAPEPTIDE; HYDROGEN; PENTAPEPTIDE; PROTON; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ARTICLE; BETA TURN; CIRCULAR DICHROISM; CONTROLLED STUDY; DIASTEREOISOMER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG PENETRATION; EPIMERIZATION; HYDROGEN BOND; MALE; METHYLATION; MOLECULAR WEIGHT; NONHUMAN; PLASMA CLEARANCE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

EID: 84907923894     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5002823     Document Type: Article

References (25)

1. Danho, W.; Swistok, J.; Khan, W.; Chu, X.-J.; Cheung, A.; Fry, D.; Sun, H.; Kurylko, G.; Rumennik, L.; Cefalu, J.; Cefalu, G.; Nunn, P. Opportunities and challenges of developing peptide drugs in the pharmaceutical industry Peptides for Youth 2009, 611, 467-469
2. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: science and market Drug Discovery Today 2010, 15, 40-56
3. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The Future of Peptide-based Drugs Chem. Biol. Drug Design 2013, 81, 136-147
4. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2001, 44, 235-249
5. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
6. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
7. Bockus, A. T.; McEwen, C. M.; Lokey, R. S. Form and function in cyclic peptide natural products: A pharmacokinetic perspective Curr. Top. Med. Chem. 2013, 13, 821-836
8. Giordanetto, F.; Kihlberg, J. Macrocyclic drugs and clinical candidates: What can medicinal chemists learn from their properties? J. Med. Chem. 2014, 57, 278-295
9. Gracia, S. R.; Gaus, K.; Sewald, N. Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry Future Med. Chem. 2009, 1, 1289-1310
10. White, T. R.; Renzelman, C. M.; Rand, A. C.; Rezai, T.; McEwen, C. M.; Gelev, V. M.; Turner, R. A.; Linington, R. G.; Leung, S. S. F.; Kalgutkar, A. S.; Bauman, J. N.; Zhang, Y. Z.; Liras, S.; Price, D. A.; Mathiowetz, A. M.; Jacobson, M. P.; Lokey, R. S. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds Nat. Chem. Biol. 2011, 7, 810-817
11. Rand, A. C.; Leung, S. S. F.; Eng, H.; Rotter, C. J.; Sharma, R.; Kalgutkar, A. S.; Zhang, Y. Z.; Varma, M. V.; Farley, K. A.; Khunte, B.; Limberakis, C.; Price, D. A.; Liras, S.; Mathiowetz, A. M.; Jacobson, M. P.; Lokey, R. S. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance MedChemComm 2012, 3, 1282-1289
12. Guimaraes, C. R. W.; Mathiowetz, A. M.; Shalaeva, M.; Goetz, G.; Liras, S. Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation J. Chem. Inf. Model. 2012, 52, 882-890
13. Borel, J. F. History of the discovery of cyclosporin and of its early pharmacological development Wien. Klin. Wochenschr. 2002, 114, 433-437
14. Noble, S.; Markham, A. Cyclosporine: A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) Drugs 1995, 50, 924-941
15. Lindbergfreijs, A.; Karlsson, M. O. Dose-dependent absorption and linear disposition of cyclosporine-a in rat Biopharm. Drug Dispersion 1994, 15, 75-86
16. Kim, S. J.; Choi, H. K.; Lee, Y. B. Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion in rats Int. J. Pharm. 2002, 249, 149-156
17. Kim, C. K.; Shin, H. J.; Yang, S. G.; Kim, J. H.; Oh, Y. K. Once-a-day oral dosing regimen of cyclosporin A: Combined therapy of cyclosporin A premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates Pharm. Res. 2001, 18, 454-459
18. Gonzalez, R. C. B.; Huwyler, J.; Walter, I.; Mountfield, R.; Bittner, B. Improved oral bioavailability of cyclosporin A in male Wistar rats: Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension Int. J. Pharm. 2002, 245, 143-151
19. Hedayati, S.; Bernareggi, A.; Rowland, M. Absorption kinetics of cyclosporine in the rat J. Pharm. Pharmacol. 1992, 44, 122-124
20. Beck, J. G.; Chatterjee, J.; Laufer, B.; Kiran, M. U.; Frank, A. O.; Neubauer, S.; Ovadia, O.; Greenberg, S.; Gilon, C.; Hoffman, A.; Kessler, H. Intestinal permeability of cyclic peptides: Common key backbone motifs identified J. Am. Chem. Soc. 2012, 134, 12125-12133
21. Chatterjee, J.; Mierke, D.; Kessler, H. N-methylated cyclic pentaalanine peptides as template structures J. Am. Chem. Soc. 2006, 128, 15164-15172
22. Wilson, G.; Hassan, I. F.; Dix, C. J.; Williamson, I.; Shah, R.; Mackay, M.; Artursson, P. Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier J. Controlled Release 1990, 11, 25-40
23. Artursson, P.; Palm, K.; Luthman, K. Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv. Drug Delivery Rev. 2012, 64, 280-289
24. Ovadia, O.; Greenberg, S.; Chatterjee, J.; Laufer, B.; Opperer, F.; Kessler, H.; Gilon, C.; Hoffman, A. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides Mol. Pharmaceutics 2011, 8, 479-487
25. Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y. R.; Federico, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall, S.; Fenner, K.; El-Kattan, A. F.; Liston, T. E.; Troutman, M. D. Development of a new permeability assay using low-efflux MDCKII cells J. Pharm. Sci. 2011, 100, 4974-4985